Suppr超能文献

肺动脉高压小鼠模型概述:问题与展望。

A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

机构信息

Victoria Johnson Center for Obstructive Lung Disease Research, Virginia Commonwealth University, 1220 E. Broad St., Richmond, VA 23298, USA.

出版信息

Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L977-91. doi: 10.1152/ajplung.00362.2011. Epub 2012 Feb 3.

Abstract

Many chronic pulmonary diseases are associated with pulmonary hypertension (PH) and pulmonary vascular remodeling, which is a term that continues to be used to describe a wide spectrum of vascular abnormalities. Pulmonary vascular structural changes frequently increase pulmonary vascular resistance, causing PH and right heart failure. Although rat models had been standard models of PH research, in more recent years the availability of genetically engineered mice has made this species attractive for many investigators. Here we review a large amount of data derived from experimental PH reports published since 1996. These studies using wild-type and genetically designed mice illustrate the challenges and opportunities provided by these models. Hemodynamic measurements are difficult to obtain in mice, and right heart failure has not been investigated in mice. Anatomical, cellular, and genetic differences distinguish mice and rats, and pharmacogenomics may explain the degree of PH and the particular mode of pulmonary vascular adaptation and also the response of the right ventricle.

摘要

许多慢性肺部疾病与肺动脉高压(PH)和肺血管重塑有关,肺血管重塑是一个术语,用于描述广泛的血管异常。肺血管结构的变化常增加肺血管阻力,导致 PH 和右心衰竭。虽然大鼠模型一直是 PH 研究的标准模型,但近年来,基因工程小鼠的出现使得这种物种对许多研究人员具有吸引力。在这里,我们回顾了自 1996 年以来发表的大量关于实验性 PH 的报告中的数据。这些使用野生型和基因设计的小鼠进行的研究说明了这些模型提供的挑战和机遇。血流动力学测量在小鼠中很难获得,并且尚未在小鼠中研究右心衰竭。解剖学、细胞学和遗传学的差异将小鼠和大鼠区分开来,而药物基因组学可能解释 PH 的程度以及肺血管的特定适应模式和右心室的反应。

相似文献

1
A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.
Am J Physiol Lung Cell Mol Physiol. 2012 May 15;302(10):L977-91. doi: 10.1152/ajplung.00362.2011. Epub 2012 Feb 3.
3
Alterations in cardiovascular function in an experimental model of lung fibrosis and pulmonary hypertension.
Exp Physiol. 2019 Apr;104(4):568-579. doi: 10.1113/EP087321. Epub 2019 Feb 10.
4
Right Ventricular Fibrosis.
Circulation. 2019 Jan 8;139(2):269-285. doi: 10.1161/CIRCULATIONAHA.118.035326.
6
Pioglitazone alleviates cardiac and vascular remodelling and improves survival in monocrotaline induced pulmonary arterial hypertension.
Naunyn Schmiedebergs Arch Pharmacol. 2016 Apr;389(4):369-79. doi: 10.1007/s00210-015-1205-3. Epub 2016 Jan 7.
7
Pulmonary Artery Hypertension Model in Rats by Monocrotaline Administration.
Methods Mol Biol. 2018;1816:233-241. doi: 10.1007/978-1-4939-8597-5_18.
8
Distinct loading conditions reveal various patterns of right ventricular adaptation.
Am J Physiol Heart Circ Physiol. 2013 Aug 1;305(3):H354-64. doi: 10.1152/ajpheart.00180.2013. Epub 2013 May 31.
9
Ventricular and pulmonary vascular remodeling induced by pulmonary overflow in a chronic model of pretricuspid shunt.
J Thorac Cardiovasc Surg. 2014 Dec;148(6):2609-17. doi: 10.1016/j.jtcvs.2014.04.044. Epub 2014 May 5.

引用本文的文献

2
EPA-lactone derivative, 5,6-diHETE lactone, improves pulmonary arterial hypertension in a monocrotaline-induced model.
Front Pharmacol. 2025 Jul 10;16:1621030. doi: 10.3389/fphar.2025.1621030. eCollection 2025.
5
Pulmonary vascular remodeling in Fra-2 transgenic mice is driven by type 2 inflammation and accompanied by pulmonary vascular hyperresponsiveness.
Am J Physiol Lung Cell Mol Physiol. 2025 Mar 1;328(3):L413-L429. doi: 10.1152/ajplung.00274.2024. Epub 2025 Feb 4.
6
Branched-chain α-ketoacids aerobically activate HIF1α signalling in vascular cells.
Nat Metab. 2024 Nov;6(11):2138-2156. doi: 10.1038/s42255-024-01150-4. Epub 2024 Oct 29.
7
Establishment of mouse models for severe pulmonary hypertension through 'double-hit' strategies.
Exp Physiol. 2024 Dec;109(12):2026-2030. doi: 10.1113/EP091833. Epub 2024 Sep 27.
9
LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension.
Am J Physiol Lung Cell Mol Physiol. 2024 Oct 1;327(4):L423-L438. doi: 10.1152/ajplung.00327.2023. Epub 2024 Jul 16.

本文引用的文献

2
Progenitor cells in pulmonary vascular remodeling.
Pulm Circ. 2011 Jan-Mar;1(1):3-16. doi: 10.4103/2045-8932.78095.
4
The monocrotaline model of pulmonary hypertension in perspective.
Am J Physiol Lung Cell Mol Physiol. 2012 Feb 15;302(4):L363-9. doi: 10.1152/ajplung.00212.2011. Epub 2011 Sep 30.
5
Circulating myeloid-derived suppressor cells are increased and activated in pulmonary hypertension.
Chest. 2012 Apr;141(4):944-952. doi: 10.1378/chest.11-0205. Epub 2011 Sep 22.
6
Mouse genomic variation and its effect on phenotypes and gene regulation.
Nature. 2011 Sep 14;477(7364):289-94. doi: 10.1038/nature10413.
8
Regulatory T cells limit vascular endothelial injury and prevent pulmonary hypertension.
Circ Res. 2011 Sep 30;109(8):867-79. doi: 10.1161/CIRCRESAHA.110.236927. Epub 2011 Aug 25.
9
A novel murine model of severe pulmonary arterial hypertension.
Am J Respir Crit Care Med. 2011 Nov 15;184(10):1171-82. doi: 10.1164/rccm.201103-0412OC. Epub 2011 Aug 25.
10
Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene.
Am J Physiol Lung Cell Mol Physiol. 2011 Nov;301(5):L667-74. doi: 10.1152/ajplung.00423.2010. Epub 2011 Aug 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验